Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.
D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy; D003131:Combined Modality Therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004815:Epidermal Growth Factor / Q000502:physiology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000077156:Gefitinib; D005909:Glioblastoma / Q000532:radiotherapy; D006258:Head and Neck Neoplasms / Q000532:radiotherapy; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000532:radiotherapy*; D011799:Quinazolines / Q000627:therapeutic use*; D011836:Radiation Tolerance / Q000502:physiology; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D011799:Quinazolines; D011838:Radiation-Sensitizing Agents; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D000077156:Gefitinib